Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15229912 | 0.75 | APAF1 (0.55) | GAANPSR1LMNACYP1A2CYP3A4 | |
| SCHEMBL21628148 | 0.74 | KDM4E (0.51) | GAANPSR1LMNACYP1A2CYP3A4 | |
| SCHEMBL15229985 | 0.73 | APAF1 (0.47) | GAANPSR1LMNACYP1A2CYP3A4 | |
| SCHEMBL15229836 | 0.72 | HTT (0.62) | NPSR1LMNAHTTAGTR1ALDH1A1 | |
| SCHEMBL3585241 | 0.70 | ALDH1A1 (0.67) | GAALMNACYP2C19HTTALDH1A1 | |
| SCHEMBL15231004 | 0.70 | APAF1 (0.56) | GAANPSR1LMNACYP2C19HTT | |
| SCHEMBL26944228 | 0.69 | ALDH1A1 (0.61) | GAALMNACYP1A2CYP3A4CYP2C19 | |
| Ethane SCHEMBL11828584 | 0.69 | ALDH1A1 (0.65) | GAALMNACYP2C19HTTALDH1A1 | |
| SCHEMBL15230436 | 0.68 | APAF1 (0.50) | LMNACYP2C19HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL15332321 | 0.68 | GAA (0.41) | GAALMNACYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149033-B2 | Heteroaryl compound, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and antiviral composition containing same as active ingredient | INSTITUT PASTEUR KOREA (KR) | 2021-10-19 | — | — | US | disclosed |
| US-20200031816-A1 | NOVEL HETEROARYL COMPOUND, ENANTIOMER, DIASTEREOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ST PHARM CO., LTD. (KR) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031816-A1 | NOVEL HETEROARYL COMPOUND, ENANTIOMER, DIASTEREOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ZC3HAV1, ZC3HAV1L, HAVCR2 | GAA 186/4885NPSR1 2215/4885LMNA 3673/4885 |
| US-11149033-B2 | Heteroaryl compound, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and antiviral composition containing same as active ingredient | ZC3HAV1, ZC3HAV1L, HAVCR2 | GAA 284/4885NPSR1 2004/4885LMNA 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.